Baseline patient demographics and eye characteristics for DME and RVO
| Parameters | DME (n=122) | RVO (n=54) | ||||
| SRF (n=27) | Non-SRF (n=95) | P value | SRF (n=22) | Non-SRF (n=32) | P value | |
| Patient demographics | ||||||
| Mean age, years | 62.2±9.6 | 64.1±10.5 | 0.365 | 64.4±16.5 | 72.0±12.3 | 0.073 |
| Sex, male, n (%) | 20 (74%) | 56 (59%) | 0.152 | 13 (59%) | 14 (41%) | 0.268 |
| Systemic comorbidities | ||||||
| HTN | 20 (74%) | 65 (68%) | 0.573 | 13 (59%) | 22 (69%) | 0.465 |
| HL | 11 (41%) | 43 (45%) | 0.676 | 5 (23%) | 11 (34%) | 0.357 |
| DM | 27 (100%) | 95 (100%) | NA | 6 (27%) | 5 (16%) | 0.324 |
| Insulin-dependent DM | 12 (44%) | 47 (49%) | 0.644 | 0 (0%) | 2 (6%) | 0.508 |
| Eye characteristics | ||||||
| Study eye, OD (%) | 16 (59%) | 51 (54%) | 0.607 | 9 (41%) | 17 (53%) | 0.377 |
| Bilateral macular oedema, n (%) | 17 (63%) | 37 (39%) | 0.027 | 2 (9%) | 0 (0%) | 0.168 |
| PDR | ||||||
| Study eye | 3 (11%) | 29 (31%) | 0.043 | 0 (0%) | 0 (0%) | NA |
| Fellow eye | 5 (19%) | 24 (25%) | 0.468 | 0 (0%) | 0 (0%) | NA |
| Lens status, pseudophakic | ||||||
| Study eye | 7 (26%) | 35 (37%) | 0.251 | 6 (27%) | 11 (34%) | 0.373 |
| Fellow eye | 4 (15%) | 33 (35%) | 0.058 | 4 (18%) | 14 (44%) | 0.078 |
| Visual acuity, logMAR | ||||||
| Study eye | 0.648±0.354 | 0.579±0.349 | 0.399 | 0.891±0.572 | 0.838±0.630 | 0.761 |
| Fellow eye | 0.522±0.577 | 0.491±0.422 | 0.808 | 0.673±1.045 | 0.339±0.524 | 0.109 |
| SRF, n (%) | ||||||
| Study eye | 27 (100%) | 0 (0%) | <0.001 | 22 (100%) | 0 (0%) | NA |
| Fellow eye | 5 (19%) | 1 (1%) | 0.003 | 1 (5%) | 0 (0%) | 0.392 |
| IRF, n (%) | ||||||
| Study eye | 26 (96%) | 95 (100%) | 0.221 | 21 (95%) | 32 (100%) | 0.407 |
| Fellow eye | 18 (67%) | 37 (39%) | 0.022 | 2 (9%) | 0 (0%) | 0.149 |
| ERM, n (%) | ||||||
| Study eye | 8 (30%) | 22 (23%) | 0.491 | 3 (14%) | 11 (34%) | 0.088 |
| Fellow eye | 3 (11%) | 8 (8%) | 0.716 | 3 (14%) | 3 (9%) | 0.668 |
| CST (μm) | ||||||
| Study eye | 468±156 | 359±100 | 0.002 | 531±147 | 396±114 | 0.001 |
| Fellow eye | 334±125 | 274±71 | 0.031 | 269±40 | 258±30 | 0.312 |
| MCV (mm3) | ||||||
| Study eye | 12.81±2.32 | 11.32±1.46 | 0.004 | 12.16±2.61 | 11.54±1.69 | 0.350 |
| Fellow eye | 11.19±1.88 | 10.50±1.37 | 0.098 | 10.27±0.81 | 9.67±0.93 | 0.021 |
| CAT (μm) | ||||||
| Study eye | 356±64 | 315±41 | 0.004 | 338±73 | 321±47 | 0.356 |
| Fellow eye | 333±114 | 291±41 | 0.083 | 286±22 | 269±26 | 0.018 |
CAT, cube average thickness; CST, central subfield thickness; DM, diabetes mellitus; DME, diabetic macular oedema; ERM, epiretinal membrane; HL, hyperlipidemia; HTN, hypertension; IRF, intraretinal fluid; MCV, macular cube volume; NA, not applicable; OD, right eye; PDR, proliferative diabetic retinopathy; RVO, retinal vein occlusion; SRF, subretinal fluid.